Institutional investors hold a majority ownership of PDLI through the 96.27% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2012, these large investors purchased a net $3.0 million shares.
| Mutual fund holders | 48.85% |
| Other institutional | 47.43% |
| Individual stakeholders | 2.66% |